An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody protects mice from morbidity without interfering with the development of protective immunity to subsequent homologous challenge

Wilson, Jason R.; Belser, Jessica A.; DaSilva, Juliana; Guo, Zhu; Sun, Xiangjie; Gansebom, Shane; Bai, Yaohui; Stark, Thomas J.; Chang, Jessie; Carney, Paul; Levine, Min Z.; Barnes, John; Stevens, James; Maines, Taronna R.; Tumpey, Terrence M.; York, Ian A.

doi:10.1016/j.virol.2017.08.016

Back to Previous Page

An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody protects mice from morbidity without interfering with the development of protective immunity to subsequent homologous challenge

Published Date:

Sep 06 2017

Publisher's site:

http://dx.doi.org/10.1016/j.virol.2017.08.016

Source:

Virology. 511:214-221.

[PDF-2.23 MB]

Details:

Alternative Title:

Virology

Personal Author:

Wilson, Jason R. ; Belser, Jessica A. ; DaSilva, Juliana ; Guo, Zhu ; Sun, Xiangjie ; ... More ▼

Description:

The emergence of A(H7N9) virus strains with resistance to neuraminidase (NA) inhibitors highlights a critical need to discover new countermeasures for treatment of A(H7N9) virus-infected patients. We previously described an anti-NA mAb (3c10-3) that has prophylactic and therapeutic efficacy in mice lethally challenged with A(H7N9) virus when delivered intraperitoneally (i.p.). Here we show that intrananasal (i.n.) administration of 3c10-3 protects 100% of mice from mortality when treated 24h post-challenge and further characterize the protective efficacy of 3c10-3 using a nonlethal A(H7N9) challenge model. Administration of 3c10-3 i.p. 24h prior to challenge resulted in a significant decrease in viral lung titers and deep sequencing analysis indicated that treatment did not consistently select for viral variants in NA. Furthermore, prophylactic administration of 3c10-3 did not inhibit the development of protective immunity to subsequent homologous virus re-challenge. Taken together, 3c10-3 highlights the potential use of anti-NA mAb to mitigate influenza virus infection.

Subject:

[+]

Pubmed ID:

28888111

Pubmed Central ID:

PMC5727915

Document Type:

Journal Article

Funding:

CC999999/ImCDC/Intramural CDC HHS/United States

Collection(s):

CDC Public Access

Main Document Checksum:

[+]

File Type:

Supporting Files:

	nihms924342f3.jpg	image/jpeg
	nihms924342f4.gif	image/gif
	nihms924342f4.jpg	image/jpeg
	nihms924342f5.gif	image/gif
	nihms924342f5.jpg	image/jpeg
	NIHMS924342-supplement-1.xlsx	application/vnd.openxmlformats-officedocument.spreadsheetml.sheet
	NIHMS924342-supplement-2.xlsx	application/vnd.openxmlformats-officedocument.spreadsheetml.sheet
	nihms924342.nxml	text/xml
	nihms924342f1.gif	image/gif
	nihms924342f1.jpg	image/jpeg
	nihms924342f2.gif	image/gif
	nihms924342f2.jpg	image/jpeg
	nihms924342f3.gif	image/gif

No Related Documents.

An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody protects mice from morbidity without interfering with the development of protective immunity to subsequent homologous challenge

An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody protects mice from morbidity without interfering with the development of protective immunity to subsequent homologous challenge

You May Also Like:

Have Questions?

CDC INFORMATION

CONNECT WITH CDC